News
DCTH
3.990
0.00%
0.000
BTIG Adjusts Delcath Systems' Price Target to $20 From $23, Reiterates Buy Rating
MT Newswires · 06/24 09:14
Mid-Afternoon Market Update: Dow Rises 100 Points; Kiromic BioPharma Shares Spike Higher
U.S. stocks turned higher toward the end of trading, with the Dow Jones gaining more than 100 points on Tuesday.
Benzinga · 06/07 18:50
Mid-Day Market Update: Nasdaq Turns Higher; REV Group Shares Plunge
U.S. stocks pared losses, with the Nasdaq Composite turning higher midway through trading on Tuesday.
Benzinga · 06/07 16:09
38 Stocks Moving In Tuesday's Mid-Day Session
Gainers Kiromic BioPharma, Inc. (NASDAQ: KRBP) gained 70% to $0.4900 after the company entered a sponsored research agreement under which in vivo preclinical data will be generated from Kiromic's Gamma Delta T cell allogeneic therapies.
Benzinga · 06/07 16:01
Mirati, CymaBay top healthcare gainers; Verastem, Delcath lead losers' pack
Gainers: Mirati Therapeutics (MRTX) +23%. CymaBay Therapeutics (CBAY) +16%. Veru (VERU) +9%. Kodiak Sciences (KOD) +8%. Allarity Therapeutics (ALLR) +7%. Losers: Verastem (VSTM) -12%. Delcath Systems (DCTH) -11%. Vicarious Surgical (RBOT) -8%. CEL-SCI (CVM...
Seekingalpha · 06/07 14:04
Delcath Systems Stock Jumps After Data Update From Eye Cancer Trials At ASCO Meeting
Benzinga · 06/07 11:06
Positive Initial Results From Chopin Phase 1B Trial, Focus Trial Update And QoL Study Presented At The 2022 ASCO Annual Meeting
Initial results from the Phase 1b portion of the CHOPIN trial of PHP in combination with ipilimumab plus nivolumab in advanced uveal melanoma in seven patients resulted in 85.7% Best Overall Response
Benzinga · 06/06 20:19
Positive Initial Results from CHOPIN Phase 1b Trial, FOCUS Trial Update and QoL Study Presented at the 2022 ASCO Annual Meeting
Initial results from the Phase 1b portion of the CHOPIN trial of PHP in combination with ipilimumab plus nivolumab in advanced uveal melanoma in seven patients resulted in 85.7% Best Overall Response and 100% Disease Control Rate. Median progression free s...
GlobeNewswire · 06/06 20:15
The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More
Biotech stocks reversed course along with the broader market and closed the week ending June 3 lower. The sector's lean run thus got extended.
Benzinga · 06/05 20:09
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 807 companies reached new 52-week lows.
Benzinga · 05/11 16:28
Recap: Delcath Systems Q1 Earnings
  Delcath Systems (NASDAQ:DCTH) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:30 AM. Here's what investors need to know about the announcement.
Benzinga · 05/10 14:19
Delcath Systems Q1 EPS $(1.00) Misses $(0.88) Estimate
Delcath Systems (NASDAQ:DCTH) reported quarterly losses of $(1.00) per share which missed the analyst consensus estimate of $(0.88) by 13.64 percent. This is a 3.85 percent increase over losses of $(1.04) per share from
Benzinga · 05/10 11:53
Delcath Systems GAAP EPS of -$1.00 misses by $0.12, revenue of $0.38M beats by $0.07M
Delcath Systems press release (NASDAQ:DCTH): Q1 GAAP EPS of -$1.00 misses by $0.12. Revenue of $0.38M (flat Y/Y) beats by $0.07M. On March 31, 2022, the Company had cash, cash
Seekingalpha · 05/10 11:32
Earnings Scheduled For May 10, 2022
  Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
Benzinga · 05/10 09:18
-- Earnings Flash (DCTH) DELCATH SYSTEMS Reports Q1 Loss -$1
MT Newswires · 05/10 07:54
Notable earnings before Tuesday's open
ACRS, AFCG, AGEN, AHCO, ALGM, AMRS, ANIP, ARMK, AROC, ARVL, ATNX, AUPH, AVYA, AZEK, OTCPK:BAYZF, BCO, BHC, BLDE, BLDR, BSY, CCO, CEVA, CHH, CMPS, CRNC, CRON, DBD, DCTH, DM, DS,
Seekingalpha · 05/09 15:06
Delcath Announces Poster Presentation at the 2022 ASCO Annual Meeting
NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the acceptance of a poster presentation at the upco...
GlobeNewswire · 05/09 12:30
Is Delcath Systems (NASDAQ:DCTH) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Simply Wall St. · 05/02 19:02
Delcath Systems to Host First Quarter 2022 Results
NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 10, 2022, a...
GlobeNewswire · 04/28 13:00
Canaccord Genuity Adjusts Delcath Systems' Price Target to $20 From $24, Reiterates Buy Rating
MT Newswires · 04/11 10:37
More
Webull provides a variety of real-time DCTH stock news. You can receive the latest news about Delcath Sys through multiple platforms. This information may help you make smarter investment decisions.
About DCTH
Delcath Systems, Inc. is an interventional oncology company, which is focused on the treatment of primary and metastatic liver cancers. The Company's lead product candidate, the HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) is a drug/device combination product. HEPZATO KIT is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, its commercial product is a medical device having the same device components as the HEZPATO KIT but without the melphalan hydrochloride, is designated as a Class III medical device, and is sold under the trade name CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT), where it is being used at various medical centers to treat a range of cancers of the liver. In the United States, HEPZATO KIT is considered a combination drug and device product. The Company's product administers concentrated regional chemotherapy to the liver.